Biosimilar
Comparability Studies
End-to-end biosimilarity assessment frameworks following a rigorous step-by-step model to ensure physicochemical, biological, and clinical equivalence.
Proven Step-by-Step Comparability
Developing a biosimilar is a complex analytical journey. At BrownBiology Laboratory, we utilize a tiered comparability strategy to prove that your molecule is "highly similar" to the reference product.
Our GMP-certified facilities and veteran scientists guide you from initial structural fingerprinting through to full clinical bioanalysis, ensuring every regulatory gate is passed with confidence.
Start Your Comparability Journey 鈫?/a>
Four Pillars of Biosimilarity
Providing a holistic view of equivalence across all critical quality attributes (CQAs).
Physicochemical Characterization
Deep-level structural analysis including primary & higher-order structure, post-translational modifications, and purity profiles using HR-MS, CD, and specialized chromatography.
Biological Activity (Potency)
Comprehensive bioanalytical frameworks assessing the functional binding and efficacy of the biosimilar against the reference product through ELISA and cell-based bioassays.
Non-Clinical Assessment
Comparative toxicological evaluations ensuring the safety profile of the biosimilar matches the innovator's benchmarks through validated GLP-compliant modules.
Clinical PK/PD Studies
High-precision pharmacokinetic and pharmacodynamic comparisons quantifying systemic equivalence in clinical settings with extreme sensitivity and regulatory rigor.
The Comparability Workflow
Reference Selection
Identifying and sourcing appropriate batches of the innovator reference product across multiple global markets.
Method Validation
Developing and validating cross-tested analytical methods to detect even subtle differences in molecular architecture.
Side-by-Side Testing
Simultaneous execution of comparability assays under identical conditions to eliminate technical variance.
Similarity Reporting
Compiling comprehensive dossiers for regulatory submission (FDA/EMA) proving biosimilarity through statistical rigor.